DIRS.INFO The most relevant business & tech news

☆ Blockbuster weight loss drug Wegovy's sales just doubled — and could heat up even more with a price cut
▼ + stars: | 2024-05-03 | by ( Shubhangi Goel | ) www.businessinsider.com time to read: +3 min

Read previewDanish drugmaker Novo Nordisk will lower prices of its weight loss drug Wegovy as it plans to raise sales volumes and navigate tough competition. Prices for the blockbuster drug fell in the first quarter. Sales of Wegovy more than doubled in the first quarter year-on-year, to 9.4 billion Danish crowns, or $1.3 billion, according to the company's earnings. They did not specify how much Novo plans to cut Wegovy's prices. AdvertisementThe Danish pharmaceutical maker, which also produces viral weight loss drug Ozempic, reported better-than-expected sales of 65 billion Danish crowns, or $9.4 billion, in the first quarter.

Persons: —, Karsten Munk Knudsen, Knudsen, Lars Fruergaard Jorgensen, Ozempic, Eli Lilly, Wegovy, Bernie Sanders, Goldman Sachs, Oprah Winfrey, Elon Musk, Charles Barkley Organizations: Service, Nordisk, Business Locations: Danish, Novo

☆ Promise of Eli Lilly's weight-loss drug for sleep apnea adds another reason to own the stock
▼ + stars: | 2024-04-17 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +7 min

Eli Lilly said it plans to ask U.S. regulators to expand Zepbound's label to include obstructive sleep apnea, or OSA, later this year. Shares of Eli Lilly have ridden the GLP-1 craze to new heights over the past few years. The current standard of care for obstructive sleep apnea is positive airway pressure, or PAP, machines, which help keep patients' airways open while they sleep. Analysts projected obstructive sleep apnea revenue of $3 billion. An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023.

Persons: Eli Lilly, Zepbound, it's, Mounjaro, Lilly, Jim Cramer, Jim, Eli Lilly YTD, Morgan Stanley, Jim Cramer's, Eli Lilly’s, Brendan Mcdermid Organizations: Novo Nordisk, GLP, OSA, Mayo, U.S, CNBC, Cleveland Clinic, National Council, Aging, Deutsche Bank, American Diabetes Association, Novo Nordisk's Ozempic, Bank of America Locations: U.S, Novo, New York City

☆ Novo Nordisk strikes deal worth up to $1.1 billion to expand cardio business
▼ + stars: | 2024-03-25 | by ( ) www.cnbc.com time to read: +1 min

A view of the logo of Novo Nordisk at the company's office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024. Denmark's Novo Nordisk said on Monday it had agreed to buy Cardior Pharmaceuticals for up to 1.03 billion euros ($1.1 billion) to strengthen its cardiovascular pipeline. The deal is in line with Novo's aim to expand its focus on diabetes and weight-loss therapies to include cardiovascular disease treatments. The Danish company has rocketed to become one of the world's most valuable companies on the back of its hugely popular weight-loss treatment Wegovy. The deal includes Cardior's lead compound CDR132L, currently in intermediate Phase II clinical trials for the treatment of heart failure, Novo said.

Persons: Novo, CDR132L Organizations: Novo Nordisk, Denmark's, Nordisk, Cardior Pharmaceuticals Locations: Bagsvaerd, Copenhagen, Denmark, Danish, Novo

☆ It might be time to rethink the smartphone — for real this time
▼ + stars: | 2024-03-14 | by ( Hugh Langley | ) www.businessinsider.com time to read: +5 min

Why do phones need apps? At this year's Mobile World Congress, the future of the smartphone and how we connect were firmly under the microscope. Deutsche Telekom and Brain.ai demoed one such instance at MWC: a smartphone with no apps. It's just an idea for now, but it's prompting an interesting question: Why assume the smartphone of the future has apps at all? But the smartphone industry is slumping, and there's a "need to invigorate the upgrade cycle," Milanesi told BI.

Persons: —, Sam Altman, There's, Altman, Jony, Meta's Mark Zuckerberg, Carolina Milanesi, Milanesi, Tom Butler, I'm, Butler, Lenovo's Butler, it's Organizations: Service, Congress, MWC, Las, CES, Deutsche Telekom, Brain.ai, Qualcomm, Bloomberg Locations: Carolina, PAU, AFP

☆ New AI and 5G advancements will usher in the era of edge computing on smartphones, autonomous cars, and more
▼ + stars: | 2024-03-11 | by ( Hugh Langley | ) www.businessinsider.com time to read: +5 min

The AI boom is breathing life into edge computing, which moves data processing away from the cloud. Artificial intelligence is driving us into the era of edge computing — two words you should expect to hear more in the coming months and years. Now they're expanding to edge computing, which refers to moving more of the computation closer to the user (the "edge" of the network). Amazon had eyed edge computing as a billion-dollar business, Business Insider previously reported. Jillian Kaplan, the head of global 5G at Dell, said during an MWC panel that edge computing will be a "huge energy saver."

Persons: —, Jim Poole, Poole, Aly Song, MediaTek, Tom Butler, I'm, Jillian Kaplan, Kaplan Organizations: Service, Tech, 5G, Business, Mobile, Congress, MWC, China, Lenovo, Google, Dell Locations: Barcelona, Equinix, Shanghai

☆ Novo Nordisk market cap surpasses Tesla on new obesity pill trial data
▼ + stars: | 2024-03-08 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +2 min

Liselotte Sabroe | AFP | Getty ImagesWegovy obesity drug maker Novo Nordisk surpassed Tesla in market value, after fresh early trial data showed positive results for its new experimental weight loss pill. Novo Nordisk is now the 12th most valuable company in the world, with a market cap of $604 billion — ahead of Tesla's $569 billion, according to FactSet data. 8The uptick of Thursday extends a months-long rally for Novo Nordisk, as excitement grows around weight loss drugs and their potential wider applications. The early amycretin data marks a fresh milestone for Novo Nordisk, potentially offering a more effective and less intrusive alternative to its already widely successful injection-based Wegovy and Ozempic drugs. Wegovy showed weight loss of 6% in a 12-week trial, while Ozempic is a diabetes treatment.

Persons: Liselotte Sabroe, Eli Lilly, amycretin, Martin Holst Lange, Lange Organizations: AFP, Getty, Novo Nordisk, Tesla, Microsoft Corp MSFT, Apple Inc, AAPL, NVIDIA Corp NVDA Technology, Saudi Aramco, SA Energy, Inc, AMZN Consumer, GOOGL, Berkshire Hathaway BRK.B, Company LLY Healthcare, Broadcom Inc, AVGO Technology, Taiwan Semiconductor TSM, Novo Nordisk NVO, Finance, JPMorgan Chase JPM, Reuters Locations: Bagsvaerd, Copenhagen, Denmark, Danish, London, Saudi, Mar, Europe

☆ Here are Tuesday's biggest analyst calls: Nvidia, Tesla, Apple, Microsoft, Oracle, Arm, Rivian, Lyft & more
▼ + stars: | 2024-03-05 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

Here are Tuesday's biggest calls on Wall Street: Goldman Sachs reiterates Tesla and Rivian as neutral Goldman said further price cuts are needed for Tesla and Rivian. Morgan Stanley downgrades Sunnova to equal weight from overweight Morgan Stanley said in its downgrade of the solar company that it sees stock "dislocation." JPMorgan upgrades Sea Limited to overweight from neutral JPMorgan said the Singapore-based internet tech conglomerate is on an "upswing." JPMorgan initiates Amphastar as overweight JPMorgan said it's bullish on shares of the pharmaceutical company. JPMorgan initiates Metagenomi as overweight JPMorgan said it's bullish on shares of the biotech company.

Persons: Goldman Sachs, Tesla, Goldman, TD Cowen, Arm's, Ian Thornton, Morgan Stanley downgrades Sunnova, Morgan Stanley, Baird, DA Davidson, it's, Jefferies, BJ's, it's bullish, Oppenheimer, Wolfe, Rosenblatt, Moffett, Philip Morris, Guggenheim Organizations: Tesla, Nvidia, NVIDIA, Microsoft, JPMorgan, Jefferies, UBS, disinflation, Barclays, Oracle, Citi, Novo Nordisk, CMD, Costco, Adobe, Williams, Apple, Cable, . Cable, Argus, Guggenheim, Lyft Locations: Singapore, China, Sonoma

☆ Here's what tech giants are betting on next — from robot dogs to smartphones you can wear on your wrist
▼ + stars: | 2024-03-01 | by ( Arjun Kharpal | ) www.cnbc.com time to read: +4 min

Arjun Kharpal | CNBCThe Mobile World Congress, the world's largest mobile show, is a place where device makers show off some of their latest innovations. Arjun Kharpal | CNBCTecno showed off an augmented reality glasses product with a video game controller attached. Arjun Kharpal | CNBCXiaomi has spent years talking up its smartphones' camera capabilities. Arjun Kharpal | CNBCChinese firm Tecno showed off a robot dog. Arjun Kharpal | CNBC

Persons: Arjun Kharpal, It's, There's, Oppo Oppo, Kharpal, CNBC Tecno, CNBC Xiaomi, German Shepherd, Tecno Organizations: Mobile, CNBC, Congress, Motorola, China's Lenovo, CNBC Lenovo, Samsung Galaxy, Samsung, CNBC Samsung Locations: Barcelona, Spain, Korean, German

☆ Here is Eli Lilly's competitive edge in GLP-1 obesity drugs and Abbott's secondary play
▼ + stars: | 2024-02-29 | by ( Jeff Marks | ) www.cnbc.com time to read: +4 min

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street.

Persons: Jim Cramer, Dow, Jim, Chris Danely, Cramer, Eaton, Eli Lilly, Lilly, Jim Cramer's Organizations: CNBC, Dow, Nasdaq, Semiconductor, Citi, Broadcom, Nvidia, Devices, Micron, Dell Technologies, Autodesk, Novo Nordisk, Abbott Laboratories, Novo, Viking, Jim Cramer's Charitable

☆ Viking stock doubled Tuesday. Here's where the next moves in the obesity space could come from
▼ + stars: | 2024-02-27 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +8 min

VKTX YTD mountain Viking shares year to date Then, Viking shares more than doubled in trading on Tuesday, putting the stock on pace to report a more than 300% year-to-date gain, after the company said its GLP-1/GIP receptor agonist VK2735 hit all its primary goals in a phase 2 clinical trial. The Tema Cardiovascular and Metabolic ETF (HRTS) , which is up 12% year to date, owns Novo, Lilly and Viking. Still early days Some analysts and investors admit it is still very early days for obesity treatment and many questions remain to be answered. "We continue to expect above consensus growth in the space, as we are bullish on adoption from payers and broader obesity uptake," Meacham wrote. For obesity only, Lilly has already gained a 38% share, despite only being in the market for 13 weeks, he said.

Persons: Eli Lilly, Geoff Meacham, Meacham, Lilly, Yuri Khodjamirian, Khodjamirian, Jeff Jonas, Becton Dickinson, Novo, BofA's Meacham, What's, Tema's, it's, Gabelli's Jonas, he's, William Blair, Andy Hsieh, Hsieh Organizations: Novo Nordisk, Bank of America, Centers for Disease Control, Zealand Pharma, Viking Therapeutics, Zealand, Food and Drug Administration, Novo, Metabolic, Therapeutics, Pharmaceuticals, Rock, AstraZeneca, Roche, Gabelli Funds, FDA, Viking, Merck, Pfizer Locations: U.S, Tema, Novo Nordisk's, GLP, Lilly

☆ Novo Nordisk and Eli Lilly rival soars 32% after promising weight-loss drug results
▼ + stars: | 2024-02-26 | by ( Jenni Reid | ) www.cnbc.com time to read: +1 min

Vials move along a conveyor at the Novo Nordisk A/S production facilities in Hillerod, Denmark, on Monday, June 12, 2023. Shares of Denmark's Zealand Pharma rocketed higher, after the company posted strong results from a trial of a liver disease treatment that has been touted as a potential competitor in the booming weight-loss drug market. The drug has "demonstrated efficacy" in people with obesity and is currently undergoing five Phase-3 trials in a clinical program for people who are overweight or obese. Analysts latched onto the drug's possible efficacity in obesity research following the latest test results, which indicated the safety of the top dosage used in that trial. Several other firms, including Eli Lilly, Roche and AstraZeneca, also seek to compete in the sector.

Persons: Ozempic, Eli Lilly, Roche Organizations: Novo Nordisk, pharma, Denmark's Zealand Pharma, U.S . Food, Drug Administration, Zealand Pharma, Nordisk, AstraZeneca Locations: Hillerod, Denmark, U.S, London, Danish

☆ Chinese tech firm Lenovo shows off a laptop with a see-through screen
▼ + stars: | 2024-02-25 | by ( Arjun Kharpal | ) www.cnbc.com time to read: +2 min

Arjun Kharpal | CNBCChinese tech giant Lenovo showed off a prototype laptop on Monday that has a see-through screen, underscoring how the world's largest PC maker is trying to innovate after a brutal couple of years for the market. Lenovo showed off some of its capabilities. In on demonstration, Lenovo showed how the laptop could identify an object behind the screen and display information about it. A side view of Lenovo's transparent laptop screen. Arjun Kharpal | CNBC

Persons: Arjun Kharpal Organizations: HK, CNBC, Lenovo, Gartner

☆ These are the only 2 ETFs that made money every year for the past decade
▼ + stars: | 2024-02-19 | by ( Ganesh Rao | ) www.cnbc.com time to read: +4 min

Two funds investing in defensive stocks are the only exchange-traded funds in the world that had a positive return every year over the past decade, CNBC Pro research has found. The two funds stood out among 8,300 equity ETFs worldwide screened by CNBC Pro using FactSet data. Over that period, the ETF more than doubled investors' money, with a cumulative total price gain of 118%. While the MSCI Healthcare index, valued in euros, dipped slightly into negative territory in 2016, 2020 and 2022, the Amundi ETF's total returns have remained positive because of the weakness in the pound sterling. However, Tabet also pointed out that the health-care sector, especially European pharma, tends to underperform in election years.

Persons: Joakim Tabet, Kepler, Tabet, Vincent Denoiseux, David Evans, Evans, Kepler Cheuvreux Organizations: CNBC, Healthcare UCITS, London Stock Exchange, TSX, Consumer Staples, CNBC Pro, Outlook Novo Nordisk, Novo Nordisk's, pharma, European pharma Locations: Canadian, Europe, Danish, Novo, U.S

☆ Here are Jim Cramer's rapid-fire takes on 5 stocks in the news Monday
▼ + stars: | 2024-02-05 | by ( Paulina Likos | ) www.cnbc.com time to read: +1 min

Jim Cramer said this deal is Novo's way to "get more product" and addresses the "tremendous shortage" of these high-demand drugs. Shares of Eli Lilly , a stock in the CNBC Investing Club 's portfolio, were also up more than 4% ahead of Tuesday's earnings. Snap – The social media firm laid off 10% of its workforce ahead of Tuesday's earnings. Jim pointed out that Club name Starbucks (SBUX) has also been experiencing the same thing. Jim said buy McDonald's stock on weakness.

Persons: Jim Cramer, Eli Lilly, Lilly, Cramer, Cigna –, Cantor Fitzgerald, Jim Organizations: Nordisk, Catalent, CNBC, Microsoft, RBC Capital, Humana, Starbucks, Mattel –, JPMorgan, Vision, Apple Locations: Danish, Israel

☆ We're calling up a health care stock from our Bullpen watch list, starting a new position
▼ + stars: | 2024-01-29 | by ( Jim Cramer | ) www.cnbc.com time to read: +7 min

Shortly after the opening bell, we're initiating a position in Abbott Laboratories (ABT), buying 275 shares at roughly $112 each. The way Abbott's stock has traded, it's acted like GLP-1s were a cure and people would no longer need these devices. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade.

Persons: Jim Cramer's, Abbott, Novo's, it's, Eli Lilly, we're, We're, Alinity, Abbott isn't, Jim Cramer, Jim Organizations: Abbott Laboratories, ABT, Jim Cramer's Charitable, Abbott, Novo Nordisk, Nutrition, JPMorgan, Pharmaceuticals, Core, GLP, Diagnostics, CNBC Locations: United States, LLY

☆ Morgan Stanley likes biopharma as a defensive play — giving one stock 119% upside
▼ + stars: | 2024-01-22 | by ( Ganesh Rao | ) www.cnbc.com time to read: +3 min

The biopharmaceutical sector is expected to offer a safe haven from macroeconomic and earnings concerns ahead of final quarterly results from companies, according to Morgan Stanley. Morgan Stanley, however, cautioned that the outlook for drug pricing reform in the U.S. poses risks for the sector. Shares of Indivior , argenx , AstraZeneca , Merck , Lonza, Sweden's Sobi, Novo Nordisk and Sandoz Group were among those listed by Morgan Stanley with a "buy" rating. In a bull case where Sublocade hits $2.2 billion in sales by 2030, Morgan Stanley sees shares rising further to 3,500 British pence. Novo Nordisk Shares of Novo Nordisk , a leader in diabetes and obesity drugs, offer a 9.4% upside, according to Morgan Stanley.

Persons: Morgan Stanley, Mark D Purcell, Sweden's, Sublocade, Thibault Boutherin, Morgan, — CNBC's Michael Bloom Organizations: Barclays, Bank of America, AstraZeneca, Merck, Lonza, Novo Nordisk, Sandoz Group, AstraZeneca AstraZeneca, British pharma, EU Locations: U.S, argenx, Novo, Indivior

☆ Missed the Novo and Lilly rally? These 4 under-the-radar anti-obesity drug stocks could soar, Berenberg says – giving one 44% upside
▼ + stars: | 2024-01-22 | by ( Ganesh Rao | ) www.cnbc.com time to read: +2 min

The anti-obesity drug market is expected to remain in focus this year after a bumper 2023 for weight loss drugmakers Novo Nordisk and Eli Lilly , according to Berenberg. GLP-1 drugs encourage the production of hormones that cause weight loss through reduced appetite. Nevertheless, Berenberg's analysts believe the bigger, underappreciated, near-term opportunity lies with companies preparing to launch generic versions of the first-generation GLP-1 drugs. Under-the-radar picks Sartorius and SKAN Group, Berenberg's "under-the-radar" pick, are also expected to benefit from manufacturing generic GLP-1 drugs. The investment bank sees Sartorius benefiting from the growing commercialization of GLP-1 drugs and forecasts shares to rise by 27% over the next 12 months.

Persons: Eli Lilly, Novo, Sandoz, Berenberg Organizations: Novo Nordisk, —, Nordisk, Novo Nordisk's Victoza, SKAN Locations: Germany, Europe, Sandoz, United States

☆ Lenovo bets its Motorola smartphone brand will be the third-biggest globally in 3 years
▼ + stars: | 2024-01-19 | by ( Arjun Kharpal | ) www.cnbc.com time to read: +2 min

In this article 992-HK Follow your favorite stocks CREATE FREE ACCOUNTA Motorola Razr Flip Smartphone kept at dispay at the launch event of the new Motorola Flip Smartphones, Motorola Razr 40 and Motorola Razr 40 Ultra, in New Delhi, India. Kabir Jhangiani | Nurphoto | Getty ImagesDAVOS, Switzerland — Motorola will likely be the third-biggest smartphone player in the world in three years, according to a top executive at Chinese tech firm Lenovo , the owner of the brand. In 2020, Lenovo rebooted the iconic Motorola Razr as a foldable smartphone. Motorola and Lenovo combined had around a 4% market share in the third quarter 2023, making it the eighth-largest player globally, according to Counterpoint Research. The executive said Motorola is looking to grow "stably" in the markets it is in until it reaches 10% market share in those places which will uplift its market share globally.

Persons: Kabir Jhangiani, Matthew Zielinski, Zielinski Organizations: HK, Motorola, Nurphoto, Getty, Lenovo, Google, Samsung, Apple, CNBC, Economic, Research Locations: dispay, New Delhi, India, DAVOS, Switzerland, Davos, U.S, America

☆ My wife will get her flowers on her birthday from AI: Lenovo exec
▼ + stars: | 2024-01-18 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailMy wife will get her flowers on her birthday from AI: Lenovo execMatthew Zielinski, Lenovo's president of international markets, considers India as the most strategic market globally and discusses what the future looks like with AI.

Persons: Matthew Zielinski Organizations: Lenovo Locations: India

Dec 5 (Reuters) - Eli Lilly (LLY.N) on Tuesday said its recently approved obesity treatment Zepbound is now available in U.S. pharmacies and could cost $550 a month for customers whose health insurance does not cover the drug, or half the list price. Wall Street analysts expect sales of Zepbound to reach about $2 billion in 2024, and for sales of Novo Nordisk's (NOVOb.CO) rival obesity drug Wegovy to hit around $7.5 billion. An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. When the U.S. Food and Drug Administration approved Zepbound in November, Lilly said it would launch after the U.S. Thanksgiving holiday. Lilly's obesity drug has the same active ingredient, tirzepatide, as its previously approved diabetes drug Mounjaro, which has been used off-label for weight loss since its 2022 launch.

Persons: Eli Lilly, Wegovy, danuglipron, Zepbound, Lilly, Mike Segar, Eli Lilly's, Patrick Wingrove, Manas Mishra, Khushi, Arun Koyyur, Alexander Smith, Bill Berkrot Organizations: Wall Street, Novo, Pfizer, Company, REUTERS, CVS, U.S . Food, Drug Administration, U.S, Thomson Locations: U.S, Branchburg , New Jersey, Indianapolis, New York, Bengaluru

☆ Keep buying this GLP-1 juggernaut that's already up nearly 50% this year, TD Cowen says
▼ + stars: | 2023-12-04 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +2 min

Novo Nordisk is blessed with an extremely promising growth outlook, according to TD Cowen. NVO YTD mountain Novo Nordisk YTD chart Novo Nordisk is one of the largest makers of glucagon-like peptide 1 drugs used to treat both diabetes and obesity. "The company's merits have been widely recognized, and its shares have outperformed, but we believe there is more gas in the tank," the TD Cowen analyst wrote. For one, the analyst expects Novo's strong revenue and earnings growth to outpace its peers, especially as the company benefits from global GLP-1 supply constraints. "We are optimistic for favorable outcomes on all fronts," the analyst wrote.

Persons: TD Cowen, Michael Nedelcovych's, Cowen, Nedelcovych, Novo's, NASH, — CNBC's Michael Bloom Organizations: Novo Nordisk, Nordisk, Novo, European Union Locations: Danish, Novo

☆ US obesity docs expect Lilly weight-loss drug to show similar heart benefit as Wegovy
▼ + stars: | 2023-12-01 | by ( Patrick Wingrove | ) www.reuters.com time to read: +5 min

REUTERS/Mike Segar Acquire Licensing RightsDec 1 (Reuters) - Some leading U.S. obesity specialists say they expect Eli Lilly’s (LLY.N) powerful weight-loss drug Zepbound will produce the same or similar heart benefits as Novo Nordisk’s (NOVOb.CO) popular Wegovy as they belong to the same class of medicines. In Novo's pivotal Wegovy trial involving 17,604 overweight and obese people without diabetes, the drug reduced incidence of heart attack, stroke or heart-related death by an impressive 20%. The product, which has the same active ingredient - tirzepatide - as its previously approved diabetes drug Mounjaro, is expected to start shipping it before the end of the year. They said they would readily prescribe Wegovy (semaglutide) if their patients' insurance did not cover Lilly’s drug, or if future trial results do not produce similar heart benefits. Lilly declined to comment on doctors' views that Zepbound might have the same or similar cardiovascular benefits as Wegovy.

Persons: Eli Lilly, Mike Segar, Eli Lilly’s, Lilly, Danish drugmaker, Edmond Wickham, Emily, Zepbound, Tirzepatide, ”, Rohit Kedia, Novo, Chad Weldy, semaglutide, tirzepatide, Farxiga, Boehringer Ingelheim, Lilly’s Jardiance, Patrick Wingrove, Caroline Humer, Bill Berkrot Organizations: Company, REUTERS, Novo, Wegovy, Virginia Commonwealth University . The, Virginia Commonwealth University . The U.S . Food, Drug Administration, Wall Street, Barclays, Providence, Stanford University, Thomson Locations: Branchburg , New Jersey, Danish, Virginia Commonwealth University . The U.S, Zepbound, U.S

☆ Why Pfizer's latest stumble in the obesity market is a boon for Eli Lilly
▼ + stars: | 2023-12-01 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +5 min

In June, the New York-based pharmaceutical giant stopped developing a different obesity pill, known as lotiglipron , due to concerns about liver safety. Meanwhile, Eli Lilly shares were mainly flat in afternoon trading, at around $591apiece. We lifted our Eli Lilly price target Friday to $630 per share, up from $600. Eli Lilly and Danish rival Novo Nordisk (NVO) are the two dominant players in the obesity market. The longer it takes for competitors to get to this burgeoning market, the more revenue first-movers Eli Lilly and Novo Nordisk can capture.

Persons: Eli Lilly, Jim Cramer, Lilly's, Novo's, Jim, Eli Lilly —, —, Eli, that's, — Novo's, Novo, semaglutide, Jim Cramer's, AJ Mast Organizations: Pfizer, Club, Novo Nordisk, Pharmaceutical, Amgen, AstraZeneca, Bank of America, U.S . National Library of Medicine, U.S . Food, Drug Administration, CNBC, Bloomberg, Getty Locations: New York, Danish, Lilly, U.S, Indianapolis , Indiana

☆ Novo Nordisk finds compounded Wegovy up to 33% impure, sues Florida pharmacies
▼ + stars: | 2023-11-30 | by ( Patrick Wingrove | ) www.reuters.com time to read: +3 min

[1/2] Injection pens of Novo Nordisk's weight-loss drug Wegovy are shown in this photo illustration in Oslo, Norway, November 21, 2023. The Danish drugmaker said it found impurities in all the drugs tested from Wells Pharmacy and Brooksville Pharmaceuticals, both based in Florida. Novo said the compounded versions of Wegovy tested from Brooksville were also less potent than advertised, with one sample shown to be at least 19% weaker than indicated. The drugmaker has already filed 12 lawsuits against medical spas, weight-loss clinics and compounding pharmacies offering products that claim to contain semaglutide. The case against Wells was filed in the U.S. District Court, Middle District of Florida, Ocala division and the suit against Brooksville in U.S. District Court, Middle District of Florida, Tampa division.

Persons: Victoria Klesty, Danish drugmaker, Novo, Brooksville, ” Jason Brett, Eli Lilly, Mounjaro, Wells, Patrick Wingrove, Josephine Mason, Bill Berkrot, Jane Merriman Organizations: REUTERS, Novo Nordisk, Wells Pharmacy, Brooksville Pharmaceuticals, U.S . Food, Drug Administration, FDA, Novo's, Middle District of, Brooksville, Thomson Locations: Oslo, Norway, Victoria, Danish, Florida, Wells, U.S, Middle District, Middle District of Florida, Ocala, Tampa

☆ Suspected fake Ozempic causes hypoglycemia in 11 in Lebanon
▼ + stars: | 2023-11-28 | by ( Patrick Wingrove | ) www.reuters.com time to read: +4 min

Three of the people who took the suspected fake Ozempic did so to control their diabetes, while four took it for weight management, Karam said. People with diabetes need to closely manage their blood sugar, which can be done with a variety of medicines including Ozempic. Lebanon's Ministry of Public Health issued two recalls related to Ozempic in January 2023, according to its website. Karam said Ozempic is neither purchased nor provided by the Ministry of Public Health. Several people have been hospitalized in Austria for hypoglycemia after taking potentially fake versions of Ozempic.

Persons: Rita Karam, Eli Lilly's, Novo's, Karam, Ozempic, Patrick Wingrove, Caroline Humer, Bill Berkrot Organizations: Lebanese Ministry of Public Health, Lebanon's Ministry of Public Health, Novo Nordisk, World Obesity, Obesity, International Diabetes Federation, Ministry of Public Health, Reuters, Thomson Locations: Lebanon, Germany, Egypt, Russia, United States, Novo, Britain, Belgium, Austria

Search resuls for: "Novo's"

25 mentions found